Kristin Stirm, Ph.D.

My research focus is on cancer immunology with a strong interest in T-cell biology, immune escape, and immunotherapies. The PhD I have received from the University of Zurich (Institute of Molecular Cancer Research, Anne Müller), where I elucidated oncogenic cytokine signaling and regulatory T-cells as novel immunotherapeutic targets for diffuse large B-cell lymphoma (Stirm et al., OncoImmunology, 2022; Stirm et al., Journal for Immunotherapy of Cancer, in revision; Hashwah et al., EMBO Mol Med., 2019; Bertram et al., Leukemia, 2022). Previously, I studied Molecular Biosciences, Major Cancer Biology at the University of Heidelberg. During my Master studies I investigated the role of PD-L1 in NASH-to-HCC transition in the laboratory of Mathias Heikenwälder at the German Cancer Research Center (DKFZ) in Heidelberg (Pfister et al., Nature, 2021), and deciphered the role of SLAMF9 in chronic lymphocytic leukemia and experimental autoimmune encephalomyelitis at the Weizmann Institute of Science in Rehovot, Israel (Sever et al., PNAS, 2019).